Janux Therapeutics



Janux Therapeutics is developing safe, effective novel immunotherapies with the company’s proprietary TRACTr technology. Janux’s TRACTr technology employs a modular design to rapidly engineer drug candidates against specific targets.

Andy Meyer
Chief Business Officer
Tighe Reardon
Acting CFO
Charles Winter
Tommy DiRaimondo
Director of Research
Marc Nasoff
Tractr Developer
Neil Gibson
Oncology Therapeutics

No teams yet!

No jobs yet!

No wires yet!

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.